Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02145091 · ClinicalTrials.gov registry record · Phase 1

Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

A Phase 1 study, sponsored by Johns Hopkins University.

Completed
Registry status
Phase 1
Development phase
40
Enrollment target

NCT02145091: Completed Phase 1 study, sponsored by Johns Hopkins University.

NCT02145091 is a Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 40 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02145091, a Phase 1 study, has completed, sponsored by Johns Hopkins University.

COMPLETED
Registry status
Phase 1
Development phase
40 participants
Enrollment target

Study Summary

This is a double-blind placebo-controlled study investigating the acute and persisting effects of psilocybin on meditation, spirituality, health, well-being, prosocial attitudes, and brain functioning.

Primary Outcome

This is a measure of changes in spirituality, personal well-being, relationships, and emotions.

Interventions

  • DRUG Placebo
  • DRUG Moderately-high dose of psilocybin
  • DRUG Moderately-low dose of psilocybin
  • DRUG Very-low dose of psilocybin

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2014-05
Est. Completion 2019-12-26
Phase Phase 1
Johns Hopkins University

1,448 total trials

What the finished NCT02145091 record still lists

NCT02145091 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% lower).

The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.

NCT02145091 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02145091 about?

NCT02145091 is a clinical study titled "Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators". This is a double-blind placebo-controlled study investigating the acute and persisting effects of psilocybin on meditation, spirituality, health, well-being, prosocial attitudes, and brain functioning.

What is the current status of trial NCT02145091?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2014-05. Estimated completion is 2019-12-26.

What interventions are being tested in trial NCT02145091?

The interventions under investigation include: Placebo (DRUG), Moderately-high dose of psilocybin (DRUG), Moderately-low dose of psilocybin (DRUG), Very-low dose of psilocybin (DRUG).

Who is sponsoring clinical trial NCT02145091?

This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02145091's enrollment target sits among peer trials

40 1130th of 2000 higher than 810 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02145091, the US trial registry maintained by the National Library of Medicine. NCT02145091 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.